CH632927A5 - Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen. - Google Patents
Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen. Download PDFInfo
- Publication number
- CH632927A5 CH632927A5 CH1378677A CH1378677A CH632927A5 CH 632927 A5 CH632927 A5 CH 632927A5 CH 1378677 A CH1378677 A CH 1378677A CH 1378677 A CH1378677 A CH 1378677A CH 632927 A5 CH632927 A5 CH 632927A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cells
- substances
- cell
- loaded
- solution
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 210000004027 cell Anatomy 0.000 claims description 144
- 239000000126 substance Substances 0.000 claims description 75
- 210000000170 cell membrane Anatomy 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 26
- 230000035699 permeability Effects 0.000 claims description 24
- 230000005684 electric field Effects 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 14
- 230000003204 osmotic effect Effects 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 230000035876 healing Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 230000010399 physical interaction Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 57
- 210000003743 erythrocyte Anatomy 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 102000009027 Albumins Human genes 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 108010059712 Pronase Proteins 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000008151 electrolyte solution Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- ZARBPJCRKSPIRN-UHFFFAOYSA-N 6-fluoro-1h-pyrimidine-2,4-dione Chemical compound FC1=CC(=O)NC(=O)N1 ZARBPJCRKSPIRN-UHFFFAOYSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- -1 phospholiphase Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2655801A DE2655801C2 (de) | 1976-12-09 | 1976-12-09 | Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH632927A5 true CH632927A5 (de) | 1982-11-15 |
Family
ID=5995087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1378677A CH632927A5 (de) | 1976-12-09 | 1977-11-11 | Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4224313A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5372890A (cg-RX-API-DMAC7.html) |
| CH (1) | CH632927A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2655801C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2373289A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1560165A (cg-RX-API-DMAC7.html) |
| IL (1) | IL53594A (cg-RX-API-DMAC7.html) |
| SE (1) | SE445294B (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2656746C2 (de) * | 1976-12-15 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verwendung von beladenen Erythrozyten |
| US4489162A (en) * | 1981-12-21 | 1984-12-18 | American Hospital Supply Corporation | Fresh blood (unfixed) hematology control |
| FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| US4478824A (en) * | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
| US4610241A (en) * | 1984-07-03 | 1986-09-09 | Gordon Robert T | Atherosclerosis treatment method |
| US4931276A (en) * | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
| DE3812816A1 (de) * | 1988-04-16 | 1989-11-02 | Lawaczeck Ruediger Dipl Phys P | Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung |
| US4935223A (en) * | 1988-08-04 | 1990-06-19 | Board Of Regents, The University Of Texas System | Labeled cells for use in imaging |
| JP3054190B2 (ja) | 1989-01-27 | 2000-06-19 | イムノリティックス・インコーポレイテッド | 良性前立腺肥大処置のための組成物および方法 |
| US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
| US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
| WO1993018397A1 (en) * | 1992-03-02 | 1993-09-16 | Streck Laboratories, Inc. | Reference control for use with manual and flow cytometric reticulocyte counting devices |
| US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| US20020111461A1 (en) * | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| EP0882448B1 (en) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| US20040071664A1 (en) * | 1999-07-23 | 2004-04-15 | Gendel Limited | Delivery of an agent |
| GB9917416D0 (cg-RX-API-DMAC7.html) * | 1999-07-23 | 1999-09-22 | Univ Ulster | |
| GB0002856D0 (en) * | 2000-02-08 | 2000-03-29 | Gendel Limited | Ultrasound sensitisation |
| GB0025147D0 (en) * | 2000-10-13 | 2000-11-29 | Torsana Diabetes Diagnostics A | Optical sensor for in situ measurement of analytes |
| US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| US9044381B2 (en) * | 2003-06-24 | 2015-06-02 | Baxter International Inc. | Method for delivering drugs to the brain |
| EP1713443A2 (en) * | 2004-01-29 | 2006-10-25 | Baxter International Inc. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| KR20070037444A (ko) * | 2004-06-15 | 2007-04-04 | 백스터 인터내셔널 인코포레이티드 | 고체 미립자성 치료제의 생체외 적용방법 |
| EP2259798B1 (en) | 2008-03-05 | 2013-12-11 | Baxter International Inc. | Surface-modified particles and methods for targeted drug delivery |
| DE102008029172A1 (de) | 2008-06-19 | 2009-12-24 | Kenndoff, Jochen, Dr. | Verfahren zum Schutz von insbesondere verletzten oder gestressten Hautbereichen einer Zitze während des Melkvorgangs |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| IT1399590B1 (it) | 2010-04-26 | 2013-04-26 | Erydel Spa | Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti |
| ITBO20100256A1 (it) * | 2010-04-26 | 2011-10-27 | Erydel Spa | Metodo per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti |
| FR3005420B1 (fr) * | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887698A (en) * | 1973-03-12 | 1975-06-03 | Univ Leland Stanford Junior | Sacs with epitopic sites on walls enclosing stable free radicals |
| DE2326224C3 (de) | 1973-05-23 | 1975-11-13 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Verfahren zum Abtrenne», von durch chemische oder physikalisch^ Eigenschaften ausgezeichneten ionisierten Stoffen aus einer wäßrigen Lösung |
| DE2326191B2 (de) | 1973-05-23 | 1978-03-30 | Hutschenreuther Ag, 8672 Selb | Verfahren zum Herstellen eines Reliefdekors auf keramischen Erzeugnissen |
| DE2326161C2 (de) | 1973-05-23 | 1986-07-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren zum Aufbau oder zum Abbau von durch chemische Eigenschaften ausgezeichneten, in einer wäßrigen Lösung enthaltenen Stoffen |
| GB1481480A (en) * | 1974-02-02 | 1977-07-27 | Kernforschungsanlage Juelich | Process and apparatus for increasing the permeability of the membrane of cells of organisms |
| DE2656746C2 (de) * | 1976-12-15 | 1986-06-26 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verwendung von beladenen Erythrozyten |
-
1976
- 1976-12-09 DE DE2655801A patent/DE2655801C2/de not_active Expired
-
1977
- 1977-11-11 CH CH1378677A patent/CH632927A5/de not_active IP Right Cessation
- 1977-12-08 FR FR7737044A patent/FR2373289A1/fr active Granted
- 1977-12-08 SE SE7713944A patent/SE445294B/xx not_active IP Right Cessation
- 1977-12-09 JP JP14732477A patent/JPS5372890A/ja active Pending
- 1977-12-09 GB GB51329/77A patent/GB1560165A/en not_active Expired
- 1977-12-09 US US05/859,240 patent/US4224313A/en not_active Expired - Lifetime
- 1977-12-13 IL IL53594A patent/IL53594A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE445294B (sv) | 1986-06-16 |
| JPS5372890A (en) | 1978-06-28 |
| FR2373289A1 (fr) | 1978-07-07 |
| SE7713944L (sv) | 1978-06-10 |
| US4224313A (en) | 1980-09-23 |
| DE2655801A1 (de) | 1978-06-22 |
| FR2373289B1 (cg-RX-API-DMAC7.html) | 1981-05-29 |
| DE2655801C2 (de) | 1986-06-26 |
| IL53594A (en) | 1981-06-29 |
| GB1560165A (en) | 1980-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH632927A5 (de) | Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen. | |
| CH632412A5 (de) | Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen. | |
| DE2656746C2 (de) | Verwendung von beladenen Erythrozyten | |
| Van Harreveld et al. | Light-and electron-microscopic changes in central nervous tissue after electrophoretic injection of glutamate | |
| US2786014A (en) | Platelet preservation | |
| DE68921945T2 (de) | Verfahren zur Lyophilisierung von Zellen Lyophilisierungsmedien und Verfahren zur Wiederherstellung von lyophilisierten Zellen. | |
| EP0100419B1 (de) | Wässrige Lösung zum Suspendieren und Lagern von Zellen, insbesondere Erythrozyten | |
| DE3106984A1 (de) | Verfahren zur herstellung eines mehrschichtigen verbundstoffs mit langzeit-freigabe | |
| DE19904785A1 (de) | Verfahren zur Herstellung von stabilem Alginatmaterial | |
| DE3432143C2 (de) | Verfahren zur Einkapselung eines einzuhüllenden Materials und so hergestellte Kapseln | |
| DE2248475B2 (de) | Verfahren zur gewinnung von hepatitissicheren, lagerungsstabilen und infundierbaren haemoglobinloesungen | |
| DE2812174A1 (de) | Die blutgerinnung nicht foerdernde, biologisch vertraegliche gegenstaende | |
| DE2349738A1 (de) | Verduennungsmittel | |
| DE3104815C2 (de) | Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe | |
| DE3925680A1 (de) | Verfahren zur herstellung vitaler wirkstoff-beladener humanerythrozyten | |
| Cifkova et al. | Irritation effects of residual products derived from p (HEMA) gels: II. Compounds extracted from hydrogels | |
| DE1617279A1 (de) | Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln | |
| Tani et al. | Sodium localization in the adult brain: II. Triethyltin intoxication and cerebral edema produced by epidural compression | |
| Anderson et al. | Electrophysiological observations on the digitalis-potassium interaction in canine Purkinje fibers. | |
| DE1617605B2 (de) | Verfahren zum Herstellen eines Pertussis-Antigens | |
| AT54778B (de) | Verfahren zur Gewinnung von Immunstoffen. | |
| DE932148C (de) | Verfahren zur Herstellung einer in vitro zu verwendenden stabilen Thrombokinaseloesung | |
| DE2003914A1 (de) | Immunochemisches Pharmakon zur Abtoetung von Krebszellen und Verfahren zu seiner Herstellung | |
| DE710410C (de) | Verfahren zur Erhoehung der Gerinnungsfaehigkeit von tierischem Blut | |
| Lourie et al. | Studies in Chemotherapy: XII.—The Diffusibility of the Aromatic Arsenicals into Erythrocytes and the Action of the Latter on the Pentavalent Arsenicals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |